LBA5 Capivasertib (C) + fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Phase III CAPItello-291 trial Chinese cohort.

Authors :: Hu, X.
Zhang, Q.
Sun, T.
Xiong, H.
Li, W.
Teng, Y.
Lu, Y-S.
Tseng, L-M.
Yan, M.
Li, H.
Pang, D.
Chen, S.C.
Chen, W.
Jiang, O.
Wang, J.
Wu, X.
Fan, E.
Jiang, L.
Zeng, X.
Turner, N.
Source :: Annals of Oncology. 2023 Supplement 4, Vol. 34, pS1485-S1486. 2p.
Publication Year :: 2023

Subjects :: *CLINICAL trials
*METASTATIC breast cancer
*FULVESTRANT
*AROMATASE inhibitors
*ARTIFICIAL intelligence

Full Text Access

Tools